NP001

DRUG4 trials

Sponsors

Neuraltus Pharmaceuticals, Inc., Beau Nakamoto

Conditions

Alzheimer DiseaseAmyotrophic Lateral Sclerosis

Phase 1

Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)

CompletedNCT01091142

Neuraltus Pharmaceuticals, Inc.Amyotrophic Lateral Sclerosis

Start: 2010-07-31Target: 56Updated: 2010-10-06

NP001, Alzheimer's Disease, and Blood Markers of Inflammation

TerminatedNCT03179501

Beau NakamotoAlzheimer Disease

Start: 2017-09-01End: 2018-07-31Updated: 2018-10-22

Phase 2

A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

CompletedNCT01281631

Neuraltus Pharmaceuticals, Inc.Amyotrophic Lateral Sclerosis

Start: 2011-02-28End: 2012-09-30Updated: 2012-11-22

Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation

CompletedNCT02794857

Neuraltus Pharmaceuticals, Inc.Amyotrophic Lateral Sclerosis

Start: 2016-08-29End: 2017-12-12Updated: 2018-05-07

Related Papers

The Effectiveness of NP001 on the Long-Term Survival of Patients with Amyotrophic Lateral Sclerosis

Biomedicines2024-10-163 citations